<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536949</url>
  </required_header>
  <id_info>
    <org_study_id>RVL-1201-203</org_study_id>
    <nct_id>NCT03536949</nct_id>
  </id_info>
  <brief_title>Study of Safety of RVL-1201 in Treatment of Blepharoptosis</brief_title>
  <official_title>A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RevitaLid Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RevitaLid Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment
      of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate ocular and non-ocular Adverse Events with RVL-1201 and Vehicle</measure>
    <time_frame>84 days</time_frame>
    <description>Evaluate ocular and non-ocular Adverse Events with RVL-1201 and Vehicle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of findings on Slit-lamp with RVL-1201 and Vehicle</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of findings on Slit-lamp examinations with RVL-1201 and Vehicle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of findings with Corneal fluorescein staining with RVL-1201 and Vehicle</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of findings with Corneal fluorescein staining examinations with RVL-1201 and Vehicle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of medication tolerability results</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of medication tolerability as measured by the tolerability scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Blepharoptosis</condition>
  <arm_group>
    <arm_group_label>RVL-1201 Ophthalmic Solution, 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle placebo ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVL-1201</intervention_name>
    <description>RVL-1201 ophthalmic solution, 0.1%</description>
    <arm_group_label>RVL-1201 Ophthalmic Solution, 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle ophthalmic solution</intervention_name>
    <description>Vehicle placebo ophthalmic solution</description>
    <arm_group_label>Vehicle ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Male or Female 9 years of age or older

          2. - Females must not be pregnant or planning to get pregnant and must use acceptable
             form of contraception

          3. - Must be able to self-administer study medication

          4. - Must be able to understand and sign an informed consent form. For minor subjects,
             the subject's parent or legal guardian must provide permission by signing an ICF on
             behalf of the subject and the subject should provide assent.

        Exclusion Criteria:

          1. - Congenital ptosis

          2. - Horner syndrome

          3. - Myasthenia gravis

          4. - Mechanical ptosis

          5. - Previous ptosis surgery

          6. - Resting heart rate outside the normal range

          7. - Hypertension with resting diastolic blood pressure

          8. - Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharoptosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

